{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:22:58Z","timestamp":1792002178837,"version":"4.4.0"},"reference-count":141,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Despite overwhelming epidemiological evidence, the contribution of hypertension (HTN) to heart failure (HF) development has been undermined in current clinical practice. This is because approximately half of HF patients have been labeled as suffering from HF with preserved left ventricular (LV) ejection fraction (EF) (HFpEF), with HTN, obesity, and diabetes mellitus (DM) being considered virtually equally responsible for its development. However, this suggestion is obviously inaccurate, since HTN is by far the most frequent and devastating morbidity present in HFpEF. Further, HF development in obesity or DM is rare in the absence of HTN or coronary artery disease (CAD), whereas HTN often causes HF per se. Finally, unlike HTN, for most major comorbidities present in HFpEF, including anemia, chronic kidney disease, pulmonary disease, DM, atrial fibrillation, sleep apnea, and depression, it is unknown whether they precede HF or result from it. The purpose of this paper is to provide a contemporary overview on hypertensive HF, with a special emphasis on its inflammatory nature and association with autonomic nervous system (ANS) imbalance, since both are of pathophysiologic and therapeutic interest.<\/jats:p>","DOI":"10.3390\/jcm12155090","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T11:17:17Z","timestamp":1690975037000},"page":"5090","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Hypertensive Heart Failure"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6433-4016","authenticated-orcid":false,"given":"Filippos","family":"Triposkiadis","sequence":"first","affiliation":[{"name":"School of Medicine, European University Cyprus, 2404 Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9174-4018","authenticated-orcid":false,"given":"Pantelis","family":"Sarafidis","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5740-9670","authenticated-orcid":false,"given":"Alexandros","family":"Briasoulis","sequence":"additional","affiliation":[{"name":"Department of Therapeutics, Heart Failure and Cardio-Oncology Clinic, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios E.","family":"Magouliotis","sequence":"additional","affiliation":[{"name":"Unit of Quality Improvement, Department of Cardiothoracic Surgery, University of Thessaly, 41110 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanos","family":"Athanasiou","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, St Mary\u2019s Hospital, London W2 1NY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7159-2478","authenticated-orcid":false,"given":"John","family":"Skoularigis","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital of Larissa, 41110 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9439-3946","authenticated-orcid":false,"given":"Andrew","family":"Xanthopoulos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital of Larissa, 41110 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","article-title":"Global burden of hypertension: Analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJMra1201534","article-title":"Measuring the global burden of disease","volume":"369","author":"Murray","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","article-title":"Temporal trends and patterns in heart failure incidence: A population-based study of 4 million individuals","volume":"391","author":"Conrad","year":"2018","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","article-title":"Blood pressure and incidence of twelve cardiovascular diseases: Lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people","volume":"383","author":"Rapsomaniki","year":"2014","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"n461","DOI":"10.1136\/bmj.n461","article-title":"Age dependent associations of risk factors with heart failure: Pooled population based cohort study","volume":"372","author":"Tromp","year":"2021","journal-title":"BMJ"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/cvr\/cvaa228","article-title":"Heart failure with preserved ejection fraction: Insights into diagnosis and pathophysiology","volume":"117","author":"Nagueh","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1161\/CIRCULATIONAHA.111.080770","article-title":"Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: Prevalence, therapies, and outcomes","volume":"126","author":"Steinberg","year":"2012","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1056\/NEJMc2118470","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction. Reply","volume":"386","author":"Anker","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.cardfail.2014.02.007","article-title":"The prevalence of diabetic cardiomyopathy: A population-based study in Olmsted County, Minnesota","volume":"20","author":"Dandamudi","year":"2014","journal-title":"J. Card. Fail."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1152\/physrev.00030.2020","article-title":"Obesity cardiomyopathy: Evidence, mechanisms, and therapeutic implications","volume":"101","author":"Ren","year":"2021","journal-title":"Physiol. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"695792","DOI":"10.3389\/fmed.2021.695792","article-title":"The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms","volume":"8","author":"Salvatore","year":"2021","journal-title":"Front. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Triposkiadis, F., Xanthopoulos, A., Bargiota, A., Kitai, T., Katsiki, N., Farmakis, D., Skoularigis, J., Starling, R.C., and Iliodromitis, E. (2021). Diabetes Mellitus and Heart Failure. J. Clin. Med., 10.","DOI":"10.3390\/jcm10163682"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1002\/ehf2.12975","article-title":"Relative contribution of risk factors\/co-morbidities to heart failure pathogenesis: Interaction with ejection fraction","volume":"7","author":"Giamouzis","year":"2020","journal-title":"ESC Heart Fail."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10741-011-9291-x","article-title":"The cardiorenal syndrome in heart failure: Cardiac? renal? syndrome?","volume":"17","author":"Triposkiadis","year":"2012","journal-title":"Heart Fail. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/ejhf.600","article-title":"Reframing the association and significance of co-morbidities in heart failure","volume":"18","author":"Triposkiadis","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/S2589-7500(22)00187-X","article-title":"Identifying and visualising multimorbidity and comorbidity patterns in patients in the English National Health Service: A population-based study","volume":"5","author":"Kuan","year":"2023","journal-title":"Lancet Digit. Health"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1161\/CIRCULATIONAHA.121.054602","article-title":"Harmonization of the American College of Cardiology\/American Heart Association and European Society of Cardiology\/European Society of Hypertension Blood Pressure\/Hypertension Guidelines: Comparisons, Reflections, and Recommendations","volume":"146","author":"Whelton","year":"2022","journal-title":"Circulation"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Triposkiadis, F., Xanthopoulos, A., Lampropoulos, K., Briasoulis, A., Sarafidis, P., Skoularigis, J., and Boudoulas, H. (2023). Aortic Stiffness: A Major Risk Factor for Multimorbidity in the Elderly. J. Clin. Med., 12.","DOI":"10.3390\/jcm12062321"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1161\/01.HYP.18.4.443","article-title":"Irvine H. Page: 1901\u20131991. The celebration of a leader","volume":"18","author":"Frohlich","year":"1991","journal-title":"Hypertension"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jash.2012.11.007","article-title":"The mosaic theory revisited: Common molecular mechanisms coordinating diverse organ and cellular events in hypertension","volume":"7","author":"Harrison","year":"2013","journal-title":"J. Am. Soc. Hypertens."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/CIRCRESAHA.121.318082","article-title":"Pathophysiology of Hypertension: The Mosaic Theory and Beyond","volume":"128","author":"Harrison","year":"2021","journal-title":"Circ. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1152\/physrev.00018.2018","article-title":"The Microbiota-Gut-Brain Axis","volume":"99","author":"Cryan","year":"2019","journal-title":"Physiol. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Tokarek, J., Budny, E., Saar, M., Kucmierz, J., Mlynarska, E., Rysz, J., and Franczyk, B. (2023). Does the Composition of Gut Microbiota Affect Hypertension? Molecular Mechanisms Involved in Increasing Blood Pressure. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021377"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41581-022-00654-0","article-title":"The gut microbiome and hypertension","volume":"19","author":"Zheng","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1161\/CIRCRESAHA.121.319816","article-title":"Gut Microbiome and Neuroinflammation in Hypertension","volume":"130","author":"Richards","year":"2022","journal-title":"Circ. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1161\/CIRCRESAHA.121.318052","article-title":"Hypertension: Do Inflammation and Immunity Hold the Key to Solving this Epidemic?","volume":"128","author":"Madhur","year":"2021","journal-title":"Circ. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"102177","DOI":"10.1016\/j.coi.2022.102177","article-title":"Gut microbiome-mediated regulation of neuroinflammation","volume":"76","author":"Bostick","year":"2022","journal-title":"Curr. Opin. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"G355","DOI":"10.1152\/ajpgi.00099.2021","article-title":"Gut microbiota and renin-angiotensin system: A complex interplay at local and systemic levels","volume":"321","author":"Jaworska","year":"2021","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.tcm.2018.01.001","article-title":"Heart failure with preserved ejection fraction: Classification based upon phenotype is essential for diagnosis and treatment","volume":"28","author":"Xanthopoulos","year":"2018","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41371-022-00769-8","article-title":"Decoding the mechanism of hypertension through multiomics profiling","volume":"37","author":"Adua","year":"2023","journal-title":"J. Hum. Hypertens."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1152\/physiolgenomics.00032.2017","article-title":"Genetic mechanisms of human hypertension and their implications for blood pressure physiology","volume":"49","author":"Seidel","year":"2017","journal-title":"Physiol. Genom."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1205475","DOI":"10.3389\/fcvm.2023.1205475","article-title":"Hypertensive heart disease: Risk factors, complications and mechanisms","volume":"10","author":"Masenga","year":"2023","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jhh.2014.36","article-title":"Myocardial remodeling in hypertension","volume":"29","author":"Nadruz","year":"2015","journal-title":"J. Hum. Hypertens."},{"key":"ref_41","unstructured":"Osler, W. (1892). The Principles and Practice of Medicine, Appleton."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jchf.2017.04.012","article-title":"The Transition From Hypertension to Heart Failure: Contemporary Update","volume":"5","author":"Messerli","year":"2017","journal-title":"JACC Heart Fail."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/jhh.2011.104","article-title":"Prevalence of left-ventricular hypertrophy in hypertension: An updated review of echocardiographic studies","volume":"26","author":"Cuspidi","year":"2012","journal-title":"J. Hum. Hypertens."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1161\/CIRCULATIONAHA.108.845792","article-title":"The progression of hypertensive heart disease","volume":"123","author":"Drazner","year":"2011","journal-title":"Circulation"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.amjcard.2013.09.028","article-title":"Left ventricular hypertrophy patterns and incidence of heart failure with preserved versus reduced ejection fraction","volume":"113","author":"Velagaleti","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e003875","DOI":"10.1161\/CIRCHEARTFAILURE.117.003875","article-title":"Significance of Ischemic Heart Disease in Patients with Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study","volume":"10","author":"Vedin","year":"2017","journal-title":"Circ. Heart Fail."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/ejhf.1945","article-title":"Prognostic impacts of dynamic cardiac structural changes in heart failure patients with preserved left ventricular ejection fraction","volume":"22","author":"Yamanaka","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.amjcard.2005.10.030","article-title":"Left ventricular geometry and survival in patients with normal left ventricular ejection fraction","volume":"97","author":"Milani","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/1573402115666191011111402","article-title":"Resistant Hypertension: Novel Insights","volume":"16","author":"Lamirault","year":"2020","journal-title":"Curr. Hypertens. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1161\/CIRCULATIONAHA.110.981431","article-title":"Systolic and diastolic heart failure are overlapping phenotypes within the heart failure spectrum","volume":"123","author":"Brutsaert","year":"2011","journal-title":"Circulation"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/eurheartj\/ehz158","article-title":"The continuous heart failure spectrum: Moving beyond an ejection fraction classification","volume":"40","author":"Triposkiadis","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10741-020-09987-z","article-title":"Pathogenesis of chronic heart failure: Cardiovascular aging, risk factors, comorbidities, and disease modifiers","volume":"27","author":"Triposkiadis","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jacc.2019.06.053","article-title":"Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week","volume":"74","author":"Triposkiadis","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1161\/HYPERTENSIONAHA.118.12462","article-title":"Elevated Muscle Sympathetic Nerve Activity Contributes to Central Artery Stiffness in Young and Middle-Age\/Older Adults","volume":"73","author":"Holwerda","year":"2019","journal-title":"Hypertension"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"H1338","DOI":"10.1152\/ajpheart.00734.2020","article-title":"Sympathetic neural modulation of arterial stiffness in humans","volume":"319","author":"Nardone","year":"2020","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.cardfail.2021.02.011","article-title":"Exercise Intolerance in Heart Failure with Preserved Ejection Fraction: Arterial Stiffness and Aabnormal Left Ventricular Hemodynamic Responses During Exercise","volume":"27","author":"Zern","year":"2021","journal-title":"J. Card. Fail."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1093\/eurheartj\/ehv087","article-title":"The sympathetic\/parasympathetic imbalance in heart failure with reduced ejection fraction","volume":"36","author":"Floras","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1093\/eurheartjsupp\/suac030","article-title":"Sympathetic activation in heart failure","volume":"24","author":"Gronda","year":"2022","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Bencivenga, L., Palaia, M.E., Sepe, I., Gambino, G., Komici, K., Cannavo, A., Femminella, G.D., and Rengo, G. (2021). Why Do We Not Assess Sympathetic Nervous System Activity in Heart Failure Management: Might GRK2 Serve as a New Biomarker?. Cells, 10.","DOI":"10.3390\/cells10020457"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/CRD.0000000000000363","article-title":"beta-Arrestin as a Therapeutic Target in Heart Failure","volume":"29","author":"Boussi","year":"2021","journal-title":"Cardiol. Rev."},{"key":"ref_61","unstructured":"Felker, M.G., and Mann, D.L. (2019). Heart Failure: A Companion to Braunwald\u2019s Heart Disease, Elsevier."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1161\/HYPERTENSIONAHA.108.121467","article-title":"Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction","volume":"53","author":"Grassi","year":"2009","journal-title":"Hypertension"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Verloop, W.L., Beeftink, M.M., Santema, B.T., Bots, M.L., Blankestijn, P.J., Cramer, M.J., Doevendans, P.A., and Voskuil, M. (2015). A systematic review concerning the relation between the sympathetic nervous system and heart failure with preserved left ventricular ejection fraction. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0117332"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jacbts.2021.11.007","article-title":"Characterization of Cardiac Sympathetic Nervous System and Inflammatory Activation in HFpEF Patients","volume":"7","author":"Kaye","year":"2022","journal-title":"JACC Basic. Transl. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jcmg.2021.08.003","article-title":"Prognostic Significance of Cardiac (123)I-MIBG SPECT Imaging in Heart Failure Patients with Preserved Ejection Fraction","volume":"15","author":"Seo","year":"2022","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1161\/CIRCULATIONAHA.107.760405","article-title":"Parasympathetic nervous system and heart failure: Pathophysiology and potential implications for therapy","volume":"118","author":"Olshansky","year":"2008","journal-title":"Circulation"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Ramos-Martinez, I.E., Rodriguez, M.C., Cerbon, M., Ramos-Martinez, J.C., and Ramos-Martinez, E.G. (2021). Role of the Cholinergic Anti-Inflammatory Reflex in Central Nervous System Diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222413427"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e024481","DOI":"10.1161\/JAHA.121.024481","article-title":"Tackling Inflammation in Heart Failure with Preserved Ejection Fraction: Resurrection of Vagus Nerve Stimulation?","volume":"11","author":"Kittipibul","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41569-019-0315-x","article-title":"Reappraising the role of inflammation in heart failure","volume":"17","author":"Adamo","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/heartjnl-2018-314438","article-title":"Management of blood pressure in heart failure","volume":"105","author":"Rahimi","year":"2019","journal-title":"Heart"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2020-7-3","DOI":"10.7573\/dic.2020-7-3","article-title":"Role of renin-angiotensin-aldosterone system inhibitors in heart failure and chronic kidney disease","volume":"9","author":"Singhania","year":"2020","journal-title":"Drugs Context"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jjcc.2017.12.004","article-title":"A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity","volume":"71","author":"Sano","year":"2018","journal-title":"J. Cardiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/0735-1097(95)00606-0","article-title":"Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials","volume":"27","author":"Moser","year":"1996","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Mancia Chairperson, G., Kreutz Co-Chair, R., Brunstrom, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M.L., Tsioufis, K., Agabiti-Rosei, E., and Algharably, E.A.E. (2023). 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J. Hypertens.","DOI":"10.1097\/HJH.0000000000003480"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1001\/archinte.1993.00410150133013","article-title":"Hypertension: Steps forward and steps backward","volume":"153","author":"Moser","year":"1993","journal-title":"Arch. Intern. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41440-022-01158-x","article-title":"Blood pressure in heart failure management and prevention","volume":"46","author":"Maeda","year":"2023","journal-title":"Hypertens. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A Randomized Trial of Intensive versus Standard Blood-Pressure Control","volume":"373","author":"Group","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2337\/dc17-1366","article-title":"Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP","volume":"40","author":"Buckley","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1161\/HYPERTENSIONAHA.121.17682","article-title":"SPRINT Revisited: Updated Results and Implications","volume":"78","author":"Wright","year":"2021","journal-title":"Hypertension"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: An individual participant-level data meta-analysis","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/s41591-022-01974-1","article-title":"Effects of elevated systolic blood pressure on ischemic heart disease: A Burden of Proof study","volume":"28","author":"Razo","year":"2022","journal-title":"Nat. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1161\/HYPERTENSIONAHA.107.090290","article-title":"Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study","volume":"50","author":"Mancia","year":"2007","journal-title":"Hypertension"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e007131","DOI":"10.1161\/JAHA.117.007131","article-title":"Time in Therapeutic Range, as a Determinant of All-Cause Mortality in Patients with Hypertension","volume":"6","author":"Doumas","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e022765","DOI":"10.1161\/JAHA.121.022765","article-title":"Time in Target Range for Systolic Blood Pressure and Cardiovascular Outcomes in Patients with Heart Failure with Preserved Ejection Fraction","volume":"11","author":"Huang","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jchf.2022.01.010","article-title":"Prognostic Value of Time in Blood Pressure Target Range Among Patients with Heart Failure","volume":"10","author":"Chen","year":"2022","journal-title":"JACC Heart Fail."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"667","DOI":"10.4093\/dmj.2022.0215","article-title":"Blood Pressure Target in Type 2 Diabetes Mellitus","volume":"46","author":"Kim","year":"2022","journal-title":"Diabetes Metab. J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/CIRCRESAHA.122.321762","article-title":"Hypertension as Cardiovascular Risk Factor in Chronic Kidney Disease","volume":"132","author":"Burnier","year":"2023","journal-title":"Circ. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/CIRCRESAHA.116.303587","article-title":"Hypertension: Renin-angiotensin-aldosterone system alterations","volume":"116","author":"Roks","year":"2015","journal-title":"Circ. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ejhf.1149","article-title":"Heart failure with mid-range ejection fraction in CHARM: Characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum","volume":"20","author":"Lund","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1093\/eurheartj\/ehab499","article-title":"Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction","volume":"42","author":"Jackson","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/ndt\/gfac284","article-title":"Steroidal or non-steroidal MRAs: Should we still enable RAASi use through K binders?","volume":"38","author":"Gregg","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Banerjee, D., Winocour, P., Chowdhury, T.A., De, P., Wahba, M., Montero, R., Fogarty, D., Frankel, A.H., Karalliedde, J., and Mark, P.B. (2022). Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021. BMC Nephrol., 23.","DOI":"10.1186\/s12882-021-02587-5"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1125693","DOI":"10.3389\/fendo.2023.1125693","article-title":"Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus","volume":"14","author":"Ruolin","year":"2023","journal-title":"Front. Endocrinol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1161\/HYPERTENSIONAHA.121.17981","article-title":"Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease","volume":"78","author":"Jia","year":"2021","journal-title":"Hypertension"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/HJH.0000000000003330","article-title":"Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes","volume":"41","author":"Agarwal","year":"2023","journal-title":"J. Hypertens."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s11886-019-1219-4","article-title":"Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors","volume":"21","author":"Wojcik","year":"2019","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Gronda, E., Vanoli, E., Iacoviello, M., Caldarola, P., Gabrielli, D., and Tavazzi, L. (2022). The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911987"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cardfail.2021.07.003","article-title":"The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure","volume":"27","author":"Bjornstad","year":"2021","journal-title":"J. Card. Fail."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: A state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/17512433.2022.2051480","article-title":"Growing role of SGLT2i in heart failure: Evidence from clinical trials","volume":"15","author":"Varadhan","year":"2022","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Gupta, R., Maitz, T., Egeler, D., Mehta, A., Nyaeme, M., Hajra, A., Goel, A., Sreenivasan, J., Patel, N., and Aronow, W.S. (2022). SGLT2 inhibitors in hypertension: Role beyond diabetes and heart failure. Trends Cardiovasc. Med., in press.","DOI":"10.1016\/j.tcm.2022.05.005"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.pcad.2020.04.003","article-title":"Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease","volume":"63","author":"Kario","year":"2020","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1161\/CIRCULATIONAHA.121.053709","article-title":"Are SGLT2 Inhibitors New Hypertension Drugs?","volume":"143","author":"Kario","year":"2021","journal-title":"Circulation"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2020.11.029","article-title":"The Pleiotropic Effects of SGLT2 Inhibitors: Remodeling the Treatment of Heart Failure","volume":"77","author":"Goldberg","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e010283","DOI":"10.1161\/CIRCHEARTFAILURE.122.010283","article-title":"A Sweet Solution for Heart Failure with Preserved Ejection Fraction: The Role of Sodium-Glucose Cotransporter-2 Inhibitors","volume":"16","author":"Salazar","year":"2023","journal-title":"Circ. Heart Fail."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12933-022-01574-w","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: A systematic review and meta-analysis","volume":"21","author":"Li","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/ejhf.2731","article-title":"How can sodium-glucose cotransporter 2 inhibitors stimulate erythrocytosis in patients who are iron-deficient? Implications for understanding iron homeostasis in heart failure","volume":"24","author":"Packer","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1161\/HYPERTENSIONAHA.122.19020","article-title":"Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology\/European Society of Hypertension Guidelines","volume":"79","author":"Mancia","year":"2022","journal-title":"Hypertension"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Masarone, D., Martucci, M.L., Errigo, V., and Pacileo, G. (2021). The Use of beta-Blockers in Heart Failure with Reduced Ejection Fraction. J. Cardiovasc. Dev. Dis., 8.","DOI":"10.3390\/jcdd8090101"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: An individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.pcad.2005.02.001","article-title":"Neurohumoral pathways in heart failure with preserved systolic function","volume":"47","author":"Hogg","year":"2005","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e006213","DOI":"10.1161\/CIRCHEARTFAILURE.119.006213","article-title":"Heart Rate and Heart Failure with Preserved Ejection Fraction: Time to Slow beta-Blocker Use?","volume":"12","author":"Meyer","year":"2019","journal-title":"Circ. Heart Fail."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.cardfail.2021.02.015","article-title":"Medical Treatment of Heart Failure: Ignore the Ejection Fraction and Treat All?","volume":"27","author":"Triposkiadis","year":"2021","journal-title":"J. Card. Fail."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion\u2014A position statement from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1161\/HYPERTENSIONAHA.120.15205","article-title":"Pathophysiology of Diuretic Resistance and Its Implications for the Management of Chronic Heart Failure","volume":"76","author":"Wilcox","year":"2020","journal-title":"Hypertension"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/pgmj.2003.010835","article-title":"Use of diuretics in cardiovascular diseases: (1) heart failure","volume":"80","author":"Shah","year":"2004","journal-title":"Postgrad. Med. J."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/jhh.2010.64","article-title":"How early should blood pressure control be achieved for optimal cardiovascular outcomes?","volume":"25","author":"Weir","year":"2011","journal-title":"J. Hum. Hypertens."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Paczkowska-Walendowska, M., Sip, S., Staszewski, R., and Cielecka-Piontek, J. (2022). Single-Pill Combination to Improve Hypertension Treatment: Pharmaceutical Industry Development. Int. J. Environ. Res. Public. Health, 19.","DOI":"10.3390\/ijerph19074156"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s40292-019-00336-2","article-title":"Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy","volume":"26","author":"Perrone","year":"2019","journal-title":"High. Blood Press. Cardiovasc. Prev."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Gaciong, Z. (2022). Preference and Adherence to a Fixed-Dose Combination of Bisoprolol-Aspirin and Blood Pressure Control: Results of an Open-Label, Multicentre Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12010017"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Taylor, J.L., Myers, J., and Bonikowske, A.R. (2023). Practical guidelines for exercise prescription in patients with chronic heart failure. Heart Fail. Rev.","DOI":"10.1007\/s10741-023-10310-9"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Crisci, G., De Luca, M., D\u2019Assante, R., Ranieri, B., D\u2019Agostino, A., Valente, V., Giardino, F., Capone, V., Chianese, S., and Rega, S. (2022). Effects of Exercise on Heart Failure with Preserved Ejection Fraction: An Updated Review of Literature. J. Cardiovasc. Dev. Dis., 9.","DOI":"10.3390\/jcdd9080241"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"636027","DOI":"10.3389\/fphys.2021.636027","article-title":"Does Exercise Influence the Susceptibility to Arterial Thrombosis? An Integrative Perspective","volume":"12","author":"Olsen","year":"2021","journal-title":"Front. Physiol."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Daniela, M., Catalina, L., Ilie, O., Paula, M., Daniel-Andrei, I., and Ioana, B. (2022). Effects of Exercise Training on the Autonomic Nervous System with a Focus on Anti-Inflammatory and Antioxidants Effects. Antioxidants, 11.","DOI":"10.3390\/antiox11020350"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.hjc.2021.10.003","article-title":"Effects of different exercise programs on the cardiorespiratory reserve in HFpEF patients: A systematic review and meta-analysis","volume":"64","author":"Boulmpou","year":"2022","journal-title":"Hell. J. Cardiol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/HJH.0000000000002619","article-title":"Exercise training reduces arterial stiffness in adults with hypertension: A systematic review and meta-analysis","volume":"39","author":"Lopes","year":"2021","journal-title":"J. Hypertens."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"903570","DOI":"10.3389\/fcimb.2022.903570","article-title":"The Gut Microbiota (Microbiome) in Cardiovascular Disease and Its Therapeutic Regulation","volume":"12","author":"Rahman","year":"2022","journal-title":"Front. Cell Infect. Microbiol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00253-023-12369-8","article-title":"Effects of probiotics on hypertension","volume":"107","author":"Yuan","year":"2023","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.numecd.2022.09.005","article-title":"Effects of probiotics supplementation on blood pressure: An umbrella meta-analysis of randomized controlled trials","volume":"33","author":"Zarezadeh","year":"2023","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/s41440-023-01272-4","article-title":"Denervation or stimulation? Role of sympatho-vagal imbalance in HFpEF with hypertension","volume":"46","author":"Nagai","year":"2023","journal-title":"Hypertens. Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/eurheartj\/ehad054","article-title":"Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)","volume":"44","author":"Barbato","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nrendo.2012.189","article-title":"The vagus nerve and the inflammatory reflex\u2014Linking immunity and metabolism","volume":"8","author":"Pavlov","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e023582","DOI":"10.1161\/JAHA.121.023582","article-title":"Neuromodulation of Inflammation to Treat Heart Failure with Preserved Ejection Fraction: A Pilot Randomized Clinical Trial","volume":"11","author":"Stavrakis","year":"2022","journal-title":"J. Am. Heart Assoc."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/15\/5090\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:24:37Z","timestamp":1760127877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/15\/5090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,2]]},"references-count":141,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["jcm12155090"],"URL":"https:\/\/doi.org\/10.3390\/jcm12155090","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,2]]}}}